Turning Point Therapeutics Inc (TPTX) Stock
TPTX is no longer traded. Turning Point Therapeutics was acquired by Bristol Myers Squibb (BMY) on August 17, 2022.
Each TPTX share was exchanged for $76.00 in cash. Prices on this page are historical; the last trade was August 16, 2022 at $76.01.
See Bristol Myers Squibb (BMY) stock →Turning Point Therapeutics stock price history
TPTX final trading statistics
- Final close
- $76.01
- Final trading day
- Aug 16, 2022
- Market cap at delisting
- $3.81B
- Shares outstanding
- 50.07M
- Final 52-week range
- $23.77 – $82.20
- Avg. volume (final 3 mo.)
- 1,966,482
- All-time high (split-adj.)
- $147.05 · Feb 2007
- All-time low (split-adj.)
- $1.40 · Jul 2009
- Return since IPO
- -46.1%
- Beta
- -0.19
- Book value / share
- $15.90
- Price / book
- 4.78
Turning Point Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $30.83M | -$236.6M | -$4.79 |
| FY2020 | $25.00M | -$157.3M | -$3.95 |
| FY2019 | $0.00 | -$72.1M | -$5.88 |
| FY2018 | $0.00 | -$24.8M | — |
| FY2017 | $0.00 | -$16.6M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Turning Point Therapeutics Inc
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Turning Point Therapeutics stock FAQ
What happened to Turning Point Therapeutics stock?
Turning Point Therapeutics was acquired by Bristol Myers Squibb (BMY) on August 17, 2022. Shareholders received $76.00 in cash for each share. TPTX stock stopped trading on the Nasdaq, with a final close of $76.01 on August 16, 2022.
What did Turning Point Therapeutics shareholders receive?
Each TPTX share was converted into $76.00 in cash. The deal was valued at about $4.1 billion.
Is TPTX stock still trading?
No. TPTX was delisted from the Nasdaq on August 17, 2022 and no longer trades on a U.S. exchange.
What was the last price of TPTX stock?
TPTX closed at $76.01 on its final trading day, August 16, 2022, for a market value of about $3.81B.
What were Turning Point Therapeutics's revenue and earnings in its last full fiscal year?
Turning Point Therapeutics reported revenue of $30.83M and net income of -$236.6M in fiscal 2021, its last full year as a public company.
When did Turning Point Therapeutics go public?
Turning Point Therapeutics Inc stock began trading on October 4, 2006.